Yahoo Finance

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*

ZUG, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous ...
Healio

XEN1101 significantly reduced monthly seizures for adults with focal-onset epilepsy

Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...
Healio

Neurostimulation device reduces seizure frequency in adults with drug-refractory epilepsy

Please provide your email address to receive an email when new articles are posted on . Focal cortex stimulation with an implantable device reduced seizure activity in more than 50% of participants at ...
PharmiWeb

Cenobamate (ONTOZRY®), for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults, Is Now Available in the Netherlands

PARIS--(BUSINESS WIRE)--Angelini Pharma, international pharmaceutical company part of the privately held Italian Angelini Group announced today that ONTOZRY® (cenobamate) is now available in the ...
Yahoo Finance

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

LONDON, June 05, 2025--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of ...
PharmiWeb

Angelini Pharma’s Cenobamate receives approval in Ireland for use in adults with focal onset seizures in adult patients with epilepsy

Angelini Pharma’s Cenobamate receives approval in Ireland for use in adults with focal onset seizures in adult patients with epilepsy London, UK, May 15 2023 – Angelini Pharma has today announced that ...
News Medical

A novel drug reduces the monthly frequency of seizure in adults with focal epilepsy

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...
Monthly Prescribing Reference

Company Halts Clinical Program for Ganaxolone in Adult Seizures

Marinus Pharmaceuticals announced top-line results from the Phase 3 clinical trial of ganaxolone in adults with drug-resistant focal onset seizures. Marinus Pharmaceuticals announced top-line results ...
Reuters

Marinus tanks as adult focal onset seizure drug fails late stage

(Reuters) - Marinus Pharmaceuticals Inc said it plans to stop development of its treatment for drug-resistant focal onset seizures in adults after it failed a late-stage trial, sending the company's ...
Medscape

for Focal Epilepsy

The US Food and Drug Administration (FDA) has approved cenobamate (Xcopri, SK Life Science) for the treatment of partial-onset seizures in adult patients with epilepsy. Today's approval was based on ...
Finanznachrichten

Angelini Pharma: Cenobamate (ONTOZRY), for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults, Is Now Available in the Netherlands

Cenobamate use results in unprecedented seizure freedom rates for patients 1 Angelini Pharma, international pharmaceutical company part of the privately held Italian Angelini Group announced today ...